April 3rd, 2021

April 1st, 2021

On Saturday, March 20, 2021; the Chondrosarcoma CS Foundation, Inc. hosted its Second International Virtual Dialogue featuring two prominent world renown experts who introduced new techniques and innovations on how to diagnose and treat…

March 6th, 2021

Two weeks from today the Chondrosarcoma Foundation will host the Second International Virtual Dialogue. It is scheduled for Saturday, March 20, 2021 from 1:00pm – 2:30pm (EST/ New York time) on Zoom.

If you have not already, please register at…

March 1st, 2021

The Virtual Dialogue is scheduled for Saturday, March 20 at 1:00pm (Eastern Standard Time / New York). Registration for the Virtual Dialogue is still open but we are excited to share that as of today, we have 70 registrations from 10 different…

February 27th, 2021

Support Me

Howdy!

The Dolphins Challenge Cancer event will take place on April 10, 2021. The DCC is a collective community movement to raise money in support of much needed Sarcoma cancer research.

Consider…

February 14th, 2021

The registration is now open for the Chondrosarcoma Foundation’s Second International Virtual Dialogue. It is scheduled for Saturday, March 20, 2021 from 1:00pm – 2:30pm (EST/ New York time) on Zoom.

Please register at…

February 7th, 2021

Webinar Series

Global Cell Therapy Virtual Symposium

The journey from discovery to therapy begins with a single cell

The path from research to effective cancer immune cell therapies requires innovative approaches to match the challenges we face….

January 30th, 2021

One week from today is Chondrosarcoma Awareness Day. Thank you for going on our web site and signing on to support our petition for Chondrosarcoma Research and Clinical Trials. The Chondrosarcoma Foundation is initiating an international public…

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment of Soft Tissue Sarcoma (STS)

Immunicum AB (publ; IMMU.ST) announced today that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug…

Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) combination therapy in…